Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The current ratio is N/A as of Tuesday, October 6, 2026.
CURRENT RATIO
N/A
Market Cap
$13.78M
Current Ratio
0.84
TTM Avg
0.51
3Y Avg
4.20
5Y Avg
6.42
Market Cap
$14.31M
Current Ratio
1.84
TTM Avg
8.58
3Y Avg
10.61
5Y Avg
11.66
Market Cap
$14.98M
Current Ratio
26.25
TTM Avg
8.96
3Y Avg
10.61
5Y Avg
33.19
Market Cap
$12.78M
Current Ratio
6.66
TTM Avg
2.77
3Y Avg
1.93
5Y Avg
5.53
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Obsidian Therapeutics Inc. (OBX) | $14.17M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | 2.36 | 1.96 | 1.68 | 3.63 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.78M | 0.84 | 0.51 | 4.20 | 6.42 |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | 4.37 | 1.46 | 1.74 | 1.95 |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.31M | 1.84 | 8.58 | 10.61 | 11.66 |
| IN8bio, Inc. (INAB)vs › | $13.71M | 8.21 | 6.45 | 5.32 | 7.60 |
| Optimi Health Corp. (OPTH)vs › | $13.51M | 1.73 | 0.30 | 1.36 | 3.00 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.98M | 26.25 | 8.96 | 10.61 | 33.19 |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | 6.66 | 2.77 | 1.93 | 5.53 |
| Passage Bio, Inc. (PASG)vs › | $13.24M | 1.22 | 3.07 | 6.03 | 8.35 |
Current Ratio
N/A
Quick Ratio
N/A
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
